LAVAL, Quebec / Jun 06, 2024 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees |
|
| ||
|
|
|
| |
Daniel N. Chicoine | 6,490,732 | 109,026 | 98.3% | 1.7% |
Anthony E. Dobranowski | 6,508,888 | 90,870 | 98.6% | 1.4% |
John C. London | 6,533,190 | 66,568 | 99.0% | 1.0% |
Deborah Shannon-Trudeau | 6,541,297 | 58,461 | 99.1% | 0.9% |
Serge Verreault | 6,590,211 | 9,547 | 99.9% | 0.1% |
Reappointment of External Auditors
Outcome |
|
| ||
|
|
|
| |
Ernst & Young LLP reappointed | 7,212,551 | 148,556 | 98.0% | 2.0% |
Approval of the Continuation of Crescita’s Share Incentive Plan
Outcome |
|
| ||
|
|
|
| |
Share Incentive Plan approved | 6,526,477 | 73,281 | 98.9% | 1.1% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
| Last Trade: | C$0.49 |
| Daily Volume: | 0 |
| Market Cap: | C$9.270M |
May 23, 2025 March 18, 2025 November 06, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
